ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

Wegovy 0.25 mg solution for injection in pre-filled pen
Wegovy 0.5 mg solution for injection in pre-filled pen
Wegovy 1 mg solution for injection in pre-filled pen
Wegovy 1.7 mg solution for injection in pre-filled pen
Wegovy 2.4 mg solution for injection in pre-filled pen

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

**Wegovy 0.25 mg solution for injection**

Each single-use pre-filled pen contains 0.25 mg semaglutide* in 0.5 mL solution. One mL of solution contains 0.5 mg of semaglutide*.

**Wegovy 0.5 mg solution for injection**

Each single-use pre-filled pen contains 0.5 mg semaglutide* in 0.5 mL solution. One mL of solution contains 1 mg of semaglutide*.

**Wegovy 1 mg solution for injection**

Each single-use pre-filled pen contains 1 mg semaglutide* in 0.5 mL solution. One mL of solution contains 2 mg of semaglutide*.

**Wegovy 1.7 mg solution for injection**

Each single-use pre-filled pen contains 1.7 mg semaglutide* in 0.75 mL solution. One mL of solution contains 2.27 mg of semaglutide*.

**Wegovy 2.4 mg solution for injection**

Each single-use pre-filled pen contains 2.4 mg semaglutide* in 0.75 mL solution. One mL of solution contains 3.2 mg of semaglutide*.

*human glucagon-like peptide-1 (GLP-1) analogue produced in *Saccharomyces cerevisiae* cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Solution for injection (injection)
Clear and colourless isotonic solution; pH=7.4.
4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

- ≥30 kg/m\(^2\) (obesity), or
- ≥27 kg/m\(^2\) to <30 kg/m\(^2\) (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

4.2 Posology and method of administration

Posology

The maintenance dose of semaglutide 2.4 mg once-weekly is reached by starting with a dose of 0.25 mg. To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly (see Table 1). In case of significant gastrointestinal symptoms, consider delaying dose escalation or lowering to the previous dose until symptoms have improved.

<table>
<thead>
<tr>
<th>Dose escalation</th>
<th>Weekly dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 1–4</td>
<td>0.25 mg</td>
</tr>
<tr>
<td>Week 5–8</td>
<td>0.5 mg</td>
</tr>
<tr>
<td>Week 9–12</td>
<td>1 mg</td>
</tr>
<tr>
<td>Week 13–16</td>
<td>1.7 mg</td>
</tr>
<tr>
<td>Maintenance dose</td>
<td>2.4 mg</td>
</tr>
</tbody>
</table>

Weekly doses higher than 2.4 mg are not recommended.

Patients with type 2 diabetes

When initiating semaglutide in patients with type 2 diabetes, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia, see section 4.4.

Missed dose

If a dose is missed, it should be administered as soon as possible and within 5 days after the missed dose. If more than 5 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule. If more doses are missed, reducing the starting dose for re-initiation should be considered.

Special populations

Elderly (≥65 years old)

No dose adjustment is required based on age. Therapeutic experience in patients ≥75 years of age is limited, and greater sensitivity of some older individuals cannot be excluded.

Patients with renal impairment

No dose adjustment is required for patients with mild or moderate renal impairment. Experience with the use of semaglutide in patients with severe renal impairment is limited. Semaglutide is not recommended for use in patients with severe renal impairment (eGFR <30 mL/min/1.73m\(^2\)) including patients with end-stage renal disease (see sections 4.4, 4.8 and 5.2).
Patients with hepatic impairment
No dose adjustment is required for patients with mild or moderate hepatic impairment. Experience with the use of semaglutide in patients with severe hepatic impairment is limited. Semaglutide is not recommended for use in patients with severe hepatic impairment and should be used cautiously in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).

Paediatric population
The safety and efficacy of semaglutide in children and adolescents below 18 years have not yet been established. No data are available.

Method of administration
Subcutaneous use.

Wegovy is administered once weekly at any time of the day, with or without meals.

It is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. The injection site can be changed. It should not be administered intravenously or intramuscularly.

The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued.

When administering Wegovy, the pen should be pressed firmly against the skin until the yellow bar has stopped moving. The injection takes about 5–10 seconds.

Patients should be advised to read the instruction for use included in the package leaflet carefully before administering the medicinal product.

For further information before administration see section 6.6.

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Dehydration
Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions that can cause dehydration, which in rare cases can lead to a deterioration of renal function. Patients should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.

Acute pancreatitis
Acute pancreatitis has been observed with the use of GLP-1 receptor agonists (see section 4.8). Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, semaglutide should be discontinued; if confirmed, semaglutide should not be restarted. Caution should be exercised in patients with a history of pancreatitis. In the absence of other signs and symptoms of acute pancreatitis, elevations in pancreatic enzymes alone are not predictive of acute pancreatitis.
Patients with type 2 diabetes

Semaglutide should not be used as a substitute for insulin in patients with type 2 diabetes.

Semaglutide should not be used in combination with other GLP-1 receptor agonist products. It has not been evaluated and an increased risk of adverse reactions related to overdose is considered likely.

Hypoglycaemia in patients with type 2 diabetes

Insulin and sulfonylurea are known to cause hypoglycaemia. Patients treated with semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The risk of hypoglycaemia can be lowered by reducing the dose of sulfonylurea or insulin when initiating treatment with a GLP-1 receptor agonist. The addition of Wegovy in patients treated with insulin has not been evaluated.

Diabetic retinopathy in patients with type 2 diabetes

In patients with diabetic retinopathy treated with semaglutide, an increased risk of developing diabetic retinopathy complications has been observed (see section 4.8). Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, but other mechanisms cannot be excluded. Patients with diabetic retinopathy using semaglutide should be monitored closely and treated according to clinical guidelines. There is no experience with Wegovy in patients with type 2 diabetes with uncontrolled or potentially unstable diabetic retinopathy. In these patients, treatment with Wegovy is not recommended.

Populations not studied

The safety and efficacy of Wegovy have not been investigated in patients:
- treated with other products for weight management,
- with type 1 diabetes,
- with severe renal impairment (see section 4.2),
- with severe hepatic impairment (see section 4.2),
- with congestive heart failure New York Heart Association (NYHA) class IV.

Use in these patients is not recommended.

There is limited experience with Wegovy in patients:
- aged 75 years or more (see section 4.2),
- with mild or moderate hepatic impairment (see section 4.2),
- with inflammatory bowel disease,
- with diabetic gastroparesis.

Use with caution in these patients.

Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

4.5 Interaction with other medicinal products and other forms of interaction

Semaglutide delays gastric emptying and could potentially influence the absorption of concomitantly administered oral medicinal products. No clinically relevant effect on the rate of gastric emptying was observed with semaglutide 2.4 mg, probably due to a tolerance effect. Semaglutide should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption.
Paracetamol

Semaglutide delays the rate of gastric emptying as assessed by paracetamol pharmacokinetics during a standardised meal test. Paracetamol AUC$_{0-60min}$ and C$_{max}$ were decreased by 27% and 23%, respectively, following concomitant use of semaglutide 1 mg. The total paracetamol exposure (AUC$_{0-5h}$) was not affected. No clinically relevant effect on paracetamol was observed with semaglutide. No dose adjustment of paracetamol is necessary when administered with semaglutide.

Oral contraceptives

Semaglutide is not anticipated to decrease the effectiveness of oral contraceptives. It did not change the overall exposure of ethinylestradiol and levonorgestrel to a clinically relevant degree, when an oral contraceptive combination medicinal product (0.03 mg ethinylestradiol/0.15 mg levonorgestrel) was co-administered with semaglutide. Exposure of ethinylestradiol was not affected; an increase of 20% was observed for levonorgestrel exposure at steady state. C$_{max}$ was not affected for any of the compounds.

Atorvastatin

Semaglutide did not change the overall exposure of atorvastatin following a single dose administration of atorvastatin (40 mg). Atorvastatin C$_{max}$ was decreased by 38%. This was assessed not to be clinically relevant.

Digoxin

Semaglutide did not change the overall exposure or C$_{max}$ of digoxin following a single dose of digoxin (0.5 mg).

Metformin

Semaglutide did not change the overall exposure or C$_{max}$ of metformin following dosing of 500 mg twice daily over 3.5 days.

Warfarin

Semaglutide did not change overall exposure or C$_{max}$ of R- and S-warfarin following a single dose of warfarin (25 mg), and the pharmacodynamic effects of warfarin as measured by the international normalised ratio were not affected in a clinically relevant manner. However, upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of international normalised ratio (INR) is recommended.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential are recommended to use contraception when treated with semaglutide (see section 4.5).

Pregnancy

Studies in animals have shown reproductive toxicity (see section 5.3). There are limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued. Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life (see section 5.2).
Breast-feeding

In lactating rats, semaglutide was excreted in milk. A risk to a breast-fed child cannot be excluded. Semaglutide should not be used during breast-feeding.

Fertility

The effect of semaglutide on fertility in humans is unknown. Semaglutide did not affect male fertility in rats. In female rats, an increase in oestrous length and a small reduction in number of ovulations were observed at doses associated with maternal body weight loss.

4.7 Effects on ability to drive and use machines

Semaglutide has no or negligible influence on the ability to drive or use machines. However, dizziness can be experienced mainly during the dose escalation period. Driving or use of machines should be done cautiously if dizziness occurs.

Patients with type 2 diabetes

If semaglutide is used in combination with a sulfonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines (see section 4.4).

4.8 Undesirable effects

Summary of safety profile

In four phase 3a trials, 2,650 patients were exposed to Wegovy. The duration of the trials were 68 weeks. The most frequently reported adverse reactions were gastrointestinal disorders including nausea, diarrhoea, constipation and vomiting.

Tabulated list of adverse reactions

Table 2 lists adverse reactions identified in phase 3a clinical trials. The frequencies are based on a pool of the phase 3a trials.

Adverse reactions associated with Wegovy are listed by system organ class and frequency. Frequency categories are defined as: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

Table 2 Adverse reactions from controlled phase 3 trials

<table>
<thead>
<tr>
<th>MedDRA system organ class</th>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td></td>
<td>Anaphylactic reaction</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
<td></td>
<td>Hypoglycaemia in patients with type 2 diabetes⁴</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache⁴</td>
<td>Dizziness⁴</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td>Diabetic retinopathy in patients with type 2 diabetes⁴</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MedDRA system organ class</td>
<td>Very common</td>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------</td>
<td>--------</td>
<td>----------</td>
<td>------</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Vomiting&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>Diarrhoea&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>Constipation&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>Nausea&lt;sup&gt;a,b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Fatigue&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>Injection site reactions&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>see description of selected adverse reactions below  
<sup>b</sup>mainly seen in the dose-escalation period  
<sup>c</sup>Grouped preferred terms

**Description of selected adverse reactions**

**Gastrointestinal adverse reactions**
Over the 68 weeks trial period, nausea occurred in 43.9% of patients when treated with semaglutide (16.1% for placebo), diarrhoea in 29.7% (15.9% for placebo) and vomiting in 24.5% (6.3% for placebo). Most events were mild to moderate in severity and of short duration. Constipation occurred in 24.2% of patients treated with semaglutide (11.1% for placebo) and was mild to moderate in severity and of longer duration. In patients treated with semaglutide, median duration of nausea was 8 days, vomiting 2 days, diarrhoea 3 days, and constipation 47 days.

Patients with moderate renal impairment (eGFR $\geq 30$ mL/min/1.73m$^2$) may experience more gastrointestinal effects when treated with semaglutide.

The gastrointestinal events led to permanent treatment discontinuation in 4.3% of patients.

**Acute pancreatitis**
The frequency of adjudication-confirmed acute pancreatitis reported in phase 3a clinical trials was 0.2% for semaglutide and $<0.1\%$ for placebo, respectively.

**Acute gallstone disease/Cholelithiasis**
Cholelithiasis was reported in 1.6% and led to cholecystitis in 0.6% of patients treated with semaglutide. Cholelithiasis and cholecystitis was reported in 1.1% and 0.3%, respectively, of patients treated with placebo.

**Hair loss**
Hair loss was reported in 2.5% of patients treated with semaglutide and in 1.0% of patients treated with placebo. The events were mainly of mild severity and most patients recovered while on continued treatment. Hair loss was reported more frequently in patients with a greater weight loss ($\geq 20\%$).
**Increased heart rate**
In the phase 3a trials, a mean increase of 3 beats per minute (bpm) from a baseline mean of 72 bpm was observed in patients treated with semaglutide. The proportions of subjects with an increase in pulse from baseline ≥10 bpm at any timepoint during the on-treatment period were 67.0% in the semaglutide group vs. 50.1% in the placebo group.

**Immunogenicity**
Consistent with the potentially immunogenic properties of medicinal products containing proteins or peptides, patients may develop antibodies following treatment with semaglutide. The proportion of patients testing positive for anti-semaglutide antibodies at any time post-baseline was low (2.9%) and no patients had anti-semaglutide neutralising antibodies or anti-semaglutide antibodies with endogenous GLP-1 neutralising effect at end-of-trial. During treatment, high semaglutide concentrations might have lowered the sensitivity of the assays, hence the risk of false negatives cannot be excluded. However, in subjects testing positive for antibodies during and after treatment, the presence of antibodies was transient and with no apparent impact on efficacy and safety.

**Hypoglycaemia in patients with type 2 diabetes**
In STEP 2, clinically significant hypoglycaemia was observed in 6.2% (0.1 events/patient year) of subjects treated with semaglutide compared with 2.5% (0.03 events/patient year) of subjects treated with placebo. Hypoglycaemia with semaglutide was seen both with and without concomitant use of sulfonylurea. One episode (0.2% of subjects, 0.002 events/patient year) was reported as severe in a subject not concomitantly treated with a sulfonylurea. The risk of hypoglycaemia was increased when semaglutide was used with a sulfonylurea.

**Diabetic retinopathy in patients with type 2 diabetes**
A 2-year clinical trial investigated semaglutide 0.5 mg and 1 mg vs. placebo in 3,297 patients with type 2 diabetes, with high cardiovascular risk, long duration of diabetes and poorly controlled blood glucose. In this trial, adjudicated events of diabetic retinopathy complications occurred in more patients treated with semaglutide (3.0%) compared to placebo (1.8%). This was observed in insulin-treated patients with known diabetic retinopathy. The treatment difference appeared early and persisted throughout the trial. In STEP 2, retinal disorders were reported by 6.9% of patients treated with Wegovy, 6.2% of patients treated with semaglutide 1 mg, and 4.2% of patients treated with placebo. The majority of events were reported as diabetic retinopathy (4.0%, 2.7%, and 2.7%, respectively) and non-proliferative retinopathy (0.7%, 0%, and 0%, respectively).

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

### 4.9 Overdose

Overdose with semaglutide may be associated with gastrointestinal disorders which could lead to dehydration. In the event of overdose the patient should be observed for clinical signs and appropriate supportive treatment initiated.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ06
Mechanism of action

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.

GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.

Animal studies show that semaglutide works in the brain through the GLP-1 receptor. Semaglutide has direct effects on areas in the brain involved in homeostatic regulation of food intake in the hypothalamus and the brainstem. Semaglutide may affect the hedonic reward system through direct and indirect effects in brain areas including the septum, thalamus and amygdala.

Clinical studies show that semaglutide reduces energy intake, increases feelings of satiety, fullness and control of eating, reduces feelings of hunger, and frequency and intensity of cravings. In addition, semaglutide reduces the preference for high fat foods.

Semaglutide orchestrates the homeostatic and hedonic contributions with executive function to regulate caloric intake, appetite, reward and food choice.

In addition, in clinical studies semaglutide have shown to reduce blood glucose in a glucose dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. During hypoglycaemia, semaglutide diminishes insulin secretion and does not impair glucagon secretion.

GLP-1 receptors are also expressed in the heart, vasculature, immune system and kidneys. Semaglutide has a beneficial effect on plasma lipids, lowered systolic blood pressure and reduced inflammation in clinical studies. Furthermore, animal studies have shown that semaglutide attenuated the development of atherosclerosis and had an anti-inflammatory action in the cardiovascular system.

Pharmacodynamic effects

Appetite, energy intake and food choice
Semaglutide reduces appetite by increasing feelings of fullness and satiety, while lowering hunger and prospective food consumption. After 20 weeks of dosing, energy intake during an ad libitum meal was 35% lower with semaglutide compared to placebo. This was supported by improved control of eating, less food cravings and a relative lower preference for high fat food.

Fasting and postprandial lipids
Semaglutide 1 mg compared to placebo lowered fasting triglyceride and very low density lipoproteins (VLDL) concentrations by 12% and 21%, respectively. The postprandial triglyceride and VLDL response to a high fat meal was reduced with >40%.

Clinical efficacy and safety

The efficacy and safety of semaglutide for weight management in combination with a reduced calorie intake and increased physical activity were evaluated in four double-blinded randomised placebo-controlled phase 3a trials (STEP 1-4). A total of 4,684 patients (2,652 randomised to treatment with semaglutide) were included in the trials.

Treatment with semaglutide demonstrated superior, clinically meaningful, and sustained weight loss compared with placebo in patients with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m² to <30 kg/m²) and at least one weight-related comorbidity. Furthermore, across the trials, a higher proportion of patients achieved ≥5%, ≥10%, ≥15% and ≥20% weight loss with semaglutide compared
with placebo. The reduction in body weight occurred irrespective of the presence of gastrointestinal symptoms such as nausea, vomiting or diarrhoea.

Treatment with semaglutide also showed statistically significant improvements in waist circumference, systolic blood pressure and physical functioning compared to placebo.

Efficacy was demonstrated regardless of age, sex, race, ethnicity, baseline body weight, BMI, presence of type 2 diabetes and level of renal function. Variations in efficacy existed within all subgroups. Relatively greater weight loss was observed in women and in patients without type 2 diabetes as well as in patients with a lower versus higher baseline body weight.

**STEP 1: Weight management**

In a 68-week double-blind trial, 1,961 patients with obesity (BMI ≥30 kg/m²), or with overweight (BMI ≥27 kg/m² to <30 kg/m²) and at least one weight-related comorbidity were randomised to semaglutide or placebo. All patients were on a reduced-calorie diet and increased physical activity throughout the trial.

Weight loss occurred early and continued throughout the trial. At end of treatment (week 68), the weight loss was superior and clinically meaningful compared with placebo (see Table 3 and Figure 1). Furthermore, a higher proportion of patients achieved ≥5%, ≥10%, ≥15% and ≥20% weight loss with semaglutide compared with placebo (see Table 3). Among patients with prediabetes at baseline, a higher proportion of patients had a normo-glycaemic status at end of treatment with semaglutide compared to placebo (84.1% vs. 47.8%).

### Table 3 STEP 1: Results at week 68

<table>
<thead>
<tr>
<th></th>
<th>Wegovy</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full analysis set (N)</strong></td>
<td>1,306</td>
<td>655</td>
</tr>
<tr>
<td><strong>Body weight</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (kg)</td>
<td>105.4</td>
<td>105.2</td>
</tr>
<tr>
<td>Change (%) from baseline&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>-14.9</td>
<td>-2.4</td>
</tr>
<tr>
<td>Difference (%) from placebo&lt;sup&gt;1&lt;/sup&gt; [95% CI]</td>
<td>-12.4 [-13.4; -11.5]&lt;sup&gt;*&lt;/sup&gt;</td>
<td>-</td>
</tr>
<tr>
<td>Change (kg) from baseline</td>
<td>-15.3</td>
<td>-2.6</td>
</tr>
<tr>
<td>Difference (kg) from placebo&lt;sup&gt;1&lt;/sup&gt; [95% CI]</td>
<td>-12.7 [-13.7; -11.7]</td>
<td>-</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥5%&lt;sup&gt;3&lt;/sup&gt;</td>
<td>83.5*</td>
<td>31.1</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥10%&lt;sup&gt;1&lt;/sup&gt;</td>
<td>66.1*</td>
<td>12.0</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥15%&lt;sup&gt;1&lt;/sup&gt;</td>
<td>47.9*</td>
<td>4.8</td>
</tr>
<tr>
<td><strong>Waist circumference (cm)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>114.6</td>
<td>114.8</td>
</tr>
<tr>
<td>Change from baseline&lt;sup&gt;1&lt;/sup&gt;</td>
<td>-13.5</td>
<td>-4.1</td>
</tr>
<tr>
<td>Difference from placebo&lt;sup&gt;1&lt;/sup&gt; [95% CI]</td>
<td>-9.4 [-10.3; -8.5]&lt;sup&gt;*&lt;/sup&gt;</td>
<td>-</td>
</tr>
<tr>
<td><strong>Systolic blood pressure (mmHg)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>126</td>
<td>127</td>
</tr>
<tr>
<td>Change from baseline&lt;sup&gt;1&lt;/sup&gt;</td>
<td>-6.2</td>
<td>-1.1</td>
</tr>
<tr>
<td>Difference from placebo&lt;sup&gt;1&lt;/sup&gt; [95% CI]</td>
<td>-5.1 [-6.3; -3.9]&lt;sup&gt;*&lt;/sup&gt;</td>
<td>-</td>
</tr>
</tbody>
</table>

<sup>*</sup>p<0.0001 (unadjusted 2-sided) for superiority.

<sup>1</sup> Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.

<sup>2</sup> During the trial, randomised treatment was permanently discontinued by 17.1% and 22.4% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -16.9% and -2.4% for semaglutide 2.4 mg and placebo respectively.

<sup>3</sup> Estimated from binary regression model based on same imputation procedure as in primary analysis.
In a 68-week, double-blind trial, 1,210 patients with overweight or obesity (BMI ≥27 kg/m²) and type 2 diabetes were randomised to either semaglutide 2.4 mg, semaglutide 1 mg once-weekly or placebo. Patients included in the trial had insufficiently controlled diabetes (HbA₁c 7–10%) and were treated with either: diet and exercise alone or 1–3 oral antidiabetic drugs. All patients were on a reduced-calorie diet and increased physical activity throughout the trial.

Treatment with semaglutide for 68 weeks resulted in superior and clinically meaningful reduction in body weight and in HbA₁c compared to placebo (see Table 4 and Figure 2).

**Table 4** **STEP 2: Results at week 68**

<table>
<thead>
<tr>
<th></th>
<th>Wegovy</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full analysis set (N)</td>
<td>404</td>
<td>403</td>
</tr>
<tr>
<td><strong>Body weight</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (kg)</td>
<td>99.9</td>
<td>100.5</td>
</tr>
<tr>
<td>Change (%) from baseline¹²</td>
<td>-9.6</td>
<td>-3.4</td>
</tr>
<tr>
<td>Difference (%) from placebo¹ [95% CI]</td>
<td>-6.2 [-7.3;-5.2]*</td>
<td>-</td>
</tr>
<tr>
<td>Change (kg) from baseline</td>
<td>-9.7</td>
<td>-3.5</td>
</tr>
<tr>
<td>Difference (kg) from placebo¹ [95% CI]</td>
<td>-6.1 [-7.2;-5.0]</td>
<td>-</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥5%³</td>
<td>67.4*</td>
<td>30.2</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥10%³</td>
<td>44.5*</td>
<td>10.2</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥15%³</td>
<td>25.0*</td>
<td>4.3</td>
</tr>
<tr>
<td><strong>Waist circumference (cm)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>114.5</td>
<td>115.5</td>
</tr>
<tr>
<td>Change from baseline¹</td>
<td>-9.4</td>
<td>-4.5</td>
</tr>
<tr>
<td>Difference from placebo¹ [95% CI]</td>
<td>-4.9 [-6.0;-3.8]*</td>
<td>-</td>
</tr>
<tr>
<td><strong>Systolic blood pressure (mmHg)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>130</td>
<td>130</td>
</tr>
<tr>
<td>Change from baseline¹</td>
<td>-3.9</td>
<td>-0.5</td>
</tr>
<tr>
<td>Difference from placebo¹ [95% CI]</td>
<td>-3.4 [-5.6;-1.3]**</td>
<td>-</td>
</tr>
<tr>
<td><strong>HbA₁c (mmol/mol (%))</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>65.3 (8.1)</td>
<td>65.3 (8.1)</td>
</tr>
<tr>
<td>Change from baseline¹</td>
<td>-17.5 (-1.6)</td>
<td>-4.1 (-0.4)</td>
</tr>
<tr>
<td>Difference from placebo¹ [95% CI]</td>
<td>-13.5 [-15.5;-11.4]</td>
<td>-</td>
</tr>
</tbody>
</table>

Observed values for patients completing each scheduled visit, and estimates with multiple imputations (MI) from retrieved dropouts.
**p<0.0001 (unadjusted 2-sided) for superiority; **p<0.05 (unadjusted 2-sided) for superiority

During the trial, randomised treatment was permanently discontinued by 11.6% and 13.9% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -10.6% and -3.1% for semaglutide 2.4 mg and placebo respectively.

Estimated from binary regression model based on same imputation procedure as in primary analysis.

Figure 2 STEP 2: Mean change in body weight (%) from baseline to week 68

**STEP 3: Weight management with intensive behavioural therapy**

In a 68-week double-blind trial, 611 patients with obesity (BMI ≥30 kg/m²), or with overweight (BMI ≥27 kg/m² to <30 kg/m²) and at least one weight-related comorbidity were randomised to semaglutide or placebo. During the trial, all patients received intensive behavioural therapy (IBT) consisting of a very restrictive diet, increased physical activity and behavioural counselling.

Treatment with semaglutide and IBT for 68 weeks resulted in superior and clinically meaningful reduction in body weight compared to placebo (see Table 5).

**Table 5 STEP 3: Results at week 68**

<table>
<thead>
<tr>
<th></th>
<th>Wegovy</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full analysis set (N)</strong></td>
<td>407</td>
<td>204</td>
</tr>
<tr>
<td><strong>Body weight</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (kg)</td>
<td>106.9</td>
<td>103.7</td>
</tr>
<tr>
<td>Change (%) from baseline</td>
<td>-16.0</td>
<td>-5.7</td>
</tr>
<tr>
<td>Difference (%) from placebo [95% CI]</td>
<td>-10.3 [-12.0 ;-8.6]</td>
<td>-</td>
</tr>
<tr>
<td>Change (kg) from baseline</td>
<td>-16.8</td>
<td>-6.2</td>
</tr>
<tr>
<td>Difference (kg) from placebo [95% CI]</td>
<td>-10.6 [-12.5 ;-8.8]</td>
<td>-</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥5% [95% CI]</td>
<td>84.8*</td>
<td>47.8</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥10% [95% CI]</td>
<td>73.0*</td>
<td>27.1</td>
</tr>
<tr>
<td>Patients (%) achieving weight loss ≥15% [95% CI]</td>
<td>53.5*</td>
<td>13.2</td>
</tr>
<tr>
<td><strong>Waist circumference (cm)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>113.6</td>
<td>111.8</td>
</tr>
<tr>
<td>Change from baseline [95% CI]</td>
<td>-14.6</td>
<td>-6.3</td>
</tr>
<tr>
<td>Difference from placebo [95% CI]</td>
<td>-8.3 [-10.1 ;-6.6]</td>
<td>-</td>
</tr>
<tr>
<td><strong>Systolic blood pressure (mmHg)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>124</td>
<td>124</td>
</tr>
</tbody>
</table>
**STEP 4: Sustained weight management**

In a 68-week double-blind trial, 902 patients with obesity (BMI ≥30 kg/m²), or with overweight (BMI ≥27 kg/m² to <30 kg/m²) and at least one weight-related comorbidity were included in the trial. All patients were on a reduced-calorie diet and increased physical activity throughout the trial. From week 0 to week 20 (run-in), all patients received semaglutide. At week 20 (baseline), patients who had reached the maintenance dose of 2.4 mg were randomised to continue treatment or switch to placebo. At week 0 (start of run-in period) patients had a mean body weight of 107.2 kg and a mean BMI of 38.4 kg/m².

Patients who had reached the maintenance dose of 2.4 mg at week 20 (baseline) and continued treatment with semaglutide for 48 weeks (week 20–68) continued losing weight and had a superior and clinically meaningful reduction in body weight compared to those switched to placebo (see Table 6 and Figure 3). The body weight increased steadily from week 20 to week 68 in patients switching to placebo at week 20 (baseline). Nevertheless, the observed mean body weight was lower at week 68 than at start of the run-in period (week 0) (see Figure 3). Patients treated with semaglutide from week 0 (run-in) to week 68 (end of treatment) achieved a mean change in body weight of 17.4%, with weight loss ≥5% achieved by 87.8%, ≥10% achieved by 78.0%, ≥15% achieved by 62.2% and ≥20% achieved by 38.6% of these patients.

**Table 6 STEP 4: Results from week 20 to week 68**

<table>
<thead>
<tr>
<th></th>
<th>Wegovy</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body weight</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline¹ (kg)</td>
<td>96.5</td>
<td>95.4</td>
</tr>
<tr>
<td>Change (%) from baseline¹,²,³</td>
<td>-7.9</td>
<td>6.9</td>
</tr>
<tr>
<td>Difference (%) from placebo² [95% CI]</td>
<td>-14.8 [-16.0; -13.5]*</td>
<td>-</td>
</tr>
<tr>
<td>Change (kg) from baseline</td>
<td>-7.1</td>
<td>6.1</td>
</tr>
<tr>
<td>Difference (kg) from placebo² [95% CI]</td>
<td>-13.2 [-14.3; -12.0]</td>
<td>-</td>
</tr>
<tr>
<td><strong>Waist circumference (cm)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>105.5</td>
<td>104.7</td>
</tr>
<tr>
<td>Change from baseline¹</td>
<td>-6.4</td>
<td>3.3</td>
</tr>
<tr>
<td>Difference from placebo² [95% CI]</td>
<td>-9.7 [-10.9; -8.5]*</td>
<td>-</td>
</tr>
<tr>
<td><strong>Systolic blood pressure (mmHg)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline¹</td>
<td>121</td>
<td>121</td>
</tr>
<tr>
<td>Change from baseline¹</td>
<td>0.5</td>
<td>4.4</td>
</tr>
<tr>
<td>Difference from placebo² [95% CI]</td>
<td>-3.9 [-5.8; -2.0]*</td>
<td>-</td>
</tr>
</tbody>
</table>

* p<0.0001 (unadjusted 2-sided) for superiority,
1 Baseline = week 20
2 Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.
3 During the trial, randomised treatment was permanently discontinued by 5.8% and 11.6% of patients randomized to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -8.1% and 6.5% for semaglutide 2.4 mg and placebo respectively.
Figure 3 STEP 4: Mean change in body weight (%) from week 0 to week 68

**Effect on body composition**
In a sub-study in STEP 1 (N = 140), body composition was measured using dual energy X-ray absorptiometry (DEXA). The results of the DEXA assessment showed that treatment with semaglutide was accompanied by greater reduction in fat mass than in lean body mass leading to an improvement in body composition compared to placebo after 68 weeks. Furthermore, this reduction in total fat mass was accompanied by a reduction in visceral fat. These results suggest that most of the total weight loss was attributable to a reduction in fat tissue, including visceral fat.

**Improvement in physical functioning**
Semaglutide showed small improvements in physical functioning scores. Physical functioning was assessed using both the generic health-related quality of life questionnaire Short Form-36v2 Health Survey, Acute Version (SF-36) and the obesity-specific questionnaire Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT).

**Cardiovascular evaluation**
In the SUSTAIN 6 trial, 3,297 patients with insufficiently controlled type 2 diabetes and at high risk of cardiovascular events were randomised to semaglutide s.c. 0.5 mg or 1 mg once-weekly or placebo in addition to standard-of-care. The treatment duration was 104 weeks. The mean age was 65 years and the mean BMI was 33 kg/m².

The primary endpoint was the time from randomisation to first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The total number of the MACE was 254, including 108 (6.6%) with semaglutide and 146 (8.9%) with placebo.

The cardiovascular safety of treatment with semaglutide 0.5 or 1 mg was confirmed as the hazard ratio (HR) for semaglutide vs. placebo was 0.74, [0.58, 0.95] [95% CI], driven by a decrease in the rate of non-fatal stroke and non-fatal myocardial infarction with no difference in cardiovascular death (see Figure 4).
Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Wegovy in one or more subsets of the paediatric population in the treatment of weight management (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Compared to native GLP-1, semaglutide has a prolonged half-life of around 1 week making it suitable for once weekly subcutaneous administration. The principal mechanism of protraction is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilised against degradation by the DPP-4 enzyme.

Absorption

The average semaglutide steady state concentration following s.c. administration of the semaglutide maintenance dose was approximately 75 nmol/L in patients with overweight (BMI ≥27 kg/m² to <30 kg/m²) or obesity (BMI ≥ 30 kg/m²) based on data from phase 3a trials, where 90% of patients had average concentrations between 51 nmol/L and 110 nmol/L. Bioequivalence was established between exposure associated with semaglutide administered with the marketed drug product and the exposure obtained with the drug product used in phase 3a trials. The steady state exposure of semaglutide increased proportionally with doses from 0.25 mg up to 2.4 mg once weekly. Steady state exposure was stable with time as assessed up to week 68. Similar exposure was achieved with s.c. administration of semaglutide in the abdomen, thigh, or upper arm. The absolute bioavailability of semaglutide was 89%.

Distribution

The mean volume of distribution of semaglutide following s.c. administration in patients with overweight or obesity was approximately 12.4 L. Semaglutide is extensively bound to plasma albumin (>99%).

Metabolism/biotransformation

Prior to excretion, semaglutide is extensively metabolised through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain. The enzyme neutral endopeptidase (NEP) was identified as one of the active metabolic enzymes.
Elimination

The primary excretion routes of semaglutide-related material are via the urine and faeces. Approximately 3% of the absorbed dose was excreted in the urine as intact semaglutide. The clearance of semaglutide in patients with overweight (BMI ≥27 kg/m² to <30 kg/m²) or obesity (BMI ≥30 kg/m²) was approximately 0.05 L/h. With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for approximately 7 weeks after the last dose of 2.4 mg.

Special populations

Elderly
Age had no effect on the pharmacokinetics of semaglutide based on data from phase 3 trials including patients 18–86 years of age.

Gender, race and ethnicity
Gender, race (White, Black or African American, Asian) and ethnicity (Hispanic or Latino, non-Hispanic or -Latino) had no effect on the pharmacokinetics of semaglutide based on data from phase 3a trials.

Body weight
Body weight had an effect on the exposure of semaglutide. Higher body weight was associated with lower exposure; a 20% difference in body weight between individuals will result in an approximate 18% difference in exposure. The 2.4 mg weekly dose of semaglutide provided adequate systemic exposures over the body weight range of 54.4–245.6 kg evaluated for exposure response in the clinical trials.

Renal impairment
Renal impairment did not impact the pharmacokinetics of semaglutide in a clinically relevant manner. This was shown with a single dose of 0.5 mg semaglutide for patients with different degrees of renal impairment (mild, moderate, severe or patients in dialysis) compared with patients with normal renal function. This was also shown for patients with overweight (BMI ≥27 kg/m² to <30 kg/m²) or obesity (BMI ≥30 kg/m²) and mild to moderate renal impairment based on data from phase 3a trials.

Hepatic impairment
Hepatic impairment did not have any impact on the exposure of semaglutide. The pharmacokinetics of semaglutide were evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) and compared with patients with normal hepatic function in a study with a single dose of 0.5 mg semaglutide.

Prediabetes and diabetes
Prediabetes and diabetes did not have any clinically relevant effect on the exposure of semaglutide based on data from phase 3 trials.

Immunogenicity
Development of anti-semaglutide antibodies when treated with semaglutide occurred infrequently (see section 4.8) and the response did not appear to influence semaglutide pharmacokinetics.

Paediatrics
Safety and efficacy of semaglutide in children and adolescents below 18 years of age have not been studied.

5.3 Preclinical safety data

Preclinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity or genotoxicity.
Non-lethal thyroid C-cell tumours observed in rodents are a class effect for GLP-1 receptor agonists. In 2-year carcinogenicity studies in rats and mice, semaglutide caused thyroid C-cell tumours at clinically relevant exposures. No other treatment-related tumours were observed. The rodent C-cell tumours are caused by a non-genotoxic, specific GLP-1 receptor mediated mechanism to which rodents are particularly sensitive. The relevance for humans is considered to be low, but cannot be completely excluded.

In fertility studies in rats, semaglutide did not affect mating performance or male fertility. In female rats, an increase in oestrous cycle length and a small reduction in corpora lutea (ovulations) were observed at doses associated with maternal body weight loss.

In embryo-foetal development studies in rats, semaglutide caused embryotoxicity below clinically relevant exposures. Semaglutide caused marked reductions in maternal body weight and reductions in embryonic survival and growth. In foetuses, major skeletal and visceral malformations were observed, including effects on long bones, ribs, vertebrae, tail, blood vessels and brain ventricles. Mechanistic evaluations indicated that the embryotoxicity involved a GLP-1 receptor mediated impairment of the nutrient supply to the embryo across the rat yolk sac. Due to species differences in yolk sac anatomy and function, and due to lack of GLP-1 receptor expression in the yolk sac of non-human primates, this mechanism is considered unlikely to be of relevance to humans. However, a direct effect of semaglutide on the foetus cannot be excluded.

In developmental toxicity studies in rabbits and cynomolgus monkeys, increased pregnancy loss and slightly increased incidence of foetal abnormalities were observed at clinically relevant exposures. The findings coincided with marked maternal body weight loss of up to 16%. Whether these effects are related to the decreased maternal food consumption as a direct GLP-1 effect is unknown.

Postnatal growth and development were evaluated in cynomolgus monkeys. Infants were slightly smaller at delivery but recovered during the lactation period.

In juvenile rats, semaglutide caused delayed sexual maturation in both males and females. These delays had no impact upon fertility and reproductive capacity of either sex, or on the ability of the females to maintain pregnancy.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Disodium phosphate, dihydrate
Sodium chloride
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

24 months.

Wegovy may be stored unrefrigerated for up to 28 days at a temperature not above 30°C. Discard the pen if it has been out of the refrigerator for more than 28 days.
6.4 Special precautions for storage

Store in a refrigerator (2 °C-8 °C). Keep away from the cooling element. Do not freeze and do not use Wegovy if it has been frozen. Store the pen in the original carton in order to protect from light.

6.5 Nature and contents of container

1 mL glass syringe (type I glass) with attached stainless steel needle, rigid needle shield (type II/polyisoprene) and a rubber plunger (type I/chlorobutyl).

Pack sizes

4 pre-filled pens

6.6 Special precautions for disposal and other handling

The pen is for single-use only. Wegovy should not be used if it does not appear clear and colourless. The pen should not be used if it has been frozen.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

8. MARKETING AUTHORISATION NUMBERS

EU/1/21/1608/001
EU/1/21/1608/002
EU/1/21/1608/003
EU/1/21/1608/004
EU/1/21/1608/005

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation:

10. DATE OF REVISION OF THE TEXT

ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

Novo Nordisk A/S
Hallas Allé
DK-4400 Kalundborg
Denmark

Name and address of the manufacturer responsible for batch release

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARDS TO APPEAR ON THE OUTER PACKAGING

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Wegovy 0.25 mg solution for injection in pre-filled pen semaglutide

2. STATEMENT OF ACTIVE SUBSTANCE

Each pre-filled pen contains 0.25 mg semaglutide in 0.5 mL (0.5 mg/mL)

3. LIST OF EXCIPIENTS

Exipients: disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections. See leaflet for further information

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
4 pre-filled pens (1 pen delivers 1 dose)

5. METHOD AND ROUTE OF ADMINISTRATION

subcutaneous use
once weekly

Read the package leaflet before use

For single use only

Push to open

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

7. OTHER SPECIAL WARNINGS, IF NECESSARY

8. EXPIRY DATE

EXP
9. **SPECIAL STORAGE CONDITIONS**

Store in a refrigerator. Do not freeze
Keep the pen in the outer carton in order to protect from light
Discard pen after use

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

12. **MARKETING AUTHORISATION NUMBER**

EU/1/21/1608/001

13. **BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Wegovy 0.25 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC
SN
NN
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRE-FILLED PEN LABEL</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION**

   Wegovy 0.25 mg injection  
   semaglutide  
   SC

2. **METHOD OF ADMINISTRATION**

   Subcutaneous use  
   once weekly

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Batch

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

   0.5 mL  
   (1 dose)

6. **OTHER**

   Novo Nordisk A/S
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Wegovy 0.5 mg solution for injection in pre-filled pen
semaglutide

2. STATEMENT OF ACTIVE SUBSTANCE

Each pre-filled pen contains 0.5 mg semaglutide in 0.5 mL (1 mg/mL)

3. LIST OF EXCIPIENTS

Excipients: disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections. See leaflet for further information

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
4 pre-filled pens (1 pen delivers 1 dose)

5. METHOD AND ROUTE OF ADMINISTRATION

Subcutaneous use
Once weekly

Read the package leaflet before use

For single use only

Push to open

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

7. OTHER SPECIAL WARNINGS, IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze
Keep the pen in the outer carton in order to protect from light
Discard pen after use

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
    OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
    APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

12. MARKETING AUTHORISATION NUMBER

EU/1/21/1608/002

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Wegovy 0.5 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PRE-FILLED PEN LABEL**

<table>
<thead>
<tr>
<th>1. <strong>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Wegovy 0.5 mg injection semaglutide SC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. <strong>METHOD OF ADMINISTRATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous use once weekly</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. <strong>EXPIRY DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. <strong>BATCH NUMBER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. <strong>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5 mL (1 dose)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. <strong>OTHER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Novo Nordisk A/S</td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON

1. NAME OF THE MEDICINAL PRODUCT

Wegovy 1 mg solution for injection in pre-filled pen semaglutide

2. STATEMENT OF ACTIVE SUBSTANCE

Each pre-filled pen contains 1 mg semaglutide in 0.5 mL (2 mg/mL)

3. LIST OF EXCIPIENTS

Excipients: disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections. See leaflet for further information

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
4 pre-filled pens (1 pen delivers 1 dose)

5. METHOD AND ROUTE OF ADMINISTRATION

subcutaneous use
once weekly

Read the package leaflet before use

For single use only

Push to open

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

7. OTHER SPECIAL WARNINGS, IF NECESSARY

8. EXPIRY DATE

EXP
9. **SPECIAL STORAGE CONDITIONS**

Store in a refrigerator. Do not freeze
Keep the pen in the outer carton in order to protect from light
Discard pen after use

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Noovo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

12. **MARKETING AUTHORISATION NUMBER**

EU/1/21/1608/003

13. **BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Wegovy 1 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC
SN
NN
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRE-FILLED PEN LABEL</strong></td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION**
   
   Wegovy 1 mg injection  
   semaglutide  
   SC

2. **METHOD OF ADMINISTRATION**
   
   Subcutaneous use  
   once weekly

3. **EXPIRY DATE**
   
   EXP

4. **BATCH NUMBER**
   
   Batch

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**
   
   0.5 mL  
   (1 dose)

6. **OTHER**
   
   Novo Nordisk A/S
### Particulars to appear on the outer packaging

**Carton**

1. **Name of the medicinal product**
   
   Wegovy 1.7 mg solution for injection in pre-filled pen semaglutide

2. **Statement of active substance**
   
   Each pre-filled pen contains 1.7 mg semaglutide in 0.75 mL (2.27 mg/mL)

3. **List of excipients**
   
   Excipients: disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections. See leaflet for further information

4. **Pharmaceutical form and contents**
   
   Solution for injection
   
   4 pre-filled pens (1 pen delivers 1 dose)

5. **Method and route of administration**
   
   subcutaneous use
   
   once weekly
   
   Read the package leaflet before use
   
   For single use only
   
   Push to open

6. **Special warning that the medicinal product must be stored out of the sight and reach of children**
   
   Keep out of the sight and reach of children

7. **Other special warnings, if necessary**

8. **Expiry date**
   
   EXP
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze
Keep the pen in the outer carton in order to protect from light
Discard pen after use

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

12. MARKETING AUTHORISATION NUMBER

EU/1/21/1608/004

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Wegovy 1.7 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
PRE-FILLED PEN LABEL

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION**

   Wegovy 1.7 mg injection  
   semaglutide  
   SC

2. **METHOD OF ADMINISTRATION**

   Subcutaneous use  
   once weekly

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Batch

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

   0.75 mL  
   (1 dose)

6. **OTHER**

   Novo Nordisk A/S
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Wegovy 2.4 mg solution for injection in pre-filled pen
semaglutide

2. STATEMENT OF ACTIVE SUBSTANCE

Each pre-filled pen contains 2.4 mg semaglutide in 0.75 mL (3.2 mg/mL)

3. LIST OF EXCIPIENTS

Excipients: disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections. See leaflet for further information

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
4 pre-filled pens (1 pen delivers 1 dose)

5. METHOD AND ROUTE OF ADMINISTRATION

subcutaneous use
once weekly

Read the package leaflet before use

For single use only

Push to open

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children

7. OTHER SPECIAL WARNINGS, IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze
Keep the pen in the outer carton in order to protect from light
Discard pen after use

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

12. MARKETING AUTHORISATION NUMBER

EU/1/21/1608/005

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Wegovy 2.4 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION**

Wegovy 2.4 mg injection  
semaglutide  
SC

2. **METHOD OF ADMINISTRATION**

Subcutaneous use  
once weekly

3. **EXPIRY DATE**

EXP

4. **BATCH NUMBER**

Batch

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

0.75 mL  
(1 dose)

6. **OTHER**

Novo Nordisk A/S
B. PACKAGE LEAFLET
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Wegovy is and what it is used for
2. What you need to know before you use Wegovy
3. How to use Wegovy
4. Possible side effects
5. How to store Wegovy
6. Contents of the pack and other information

1. What Wegovy is and what it is used for

What Wegovy is
Wegovy is a medicine for weight loss and weight maintenance that contains the active substance semaglutide. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. It works by acting on targets (receptors) in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food. This will help you eat less food and reduce your body weight.

What Wegovy is used for
Wegovy is used together with diet and physical activity for weight loss and to help keep the weight under control. It is used in adults, who have
- a BMI of 30 kg/m² or greater (obesity) or
- a BMI of at least 27 kg/m² but less than 30 kg/m² (overweight) who have weight-related health problems (such as diabetes, high blood pressure, abnormal levels of fats in the blood, breathing problems during sleep called ‘obstructive sleep apnoea’ or a history of heart attack, stroke or blood vessel problems).

BMI (Body Mass Index) is a measure of your weight in relation to your height.

2. What you need to know before you use Wegovy

Do not use Wegovy
- if you are allergic to semaglutide or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Wegovy.

The use of Wegovy is not recommended if you:
- use other products for weight loss,
- have type 1 diabetes,
- have severely reduced kidney function,
- have severely reduced liver function,
- have severe heart failure,
- have diabetic eye disease (retinopathy).

There is little experience with Wegovy in patients:
- of 75 years and older,
- with liver problems,
- with severe stomach or gut problem which results in delayed stomach emptying (called gastroparesis), or if you have an inflammatory bowel disease.

Please consult your doctor if one of the above applies to you.

• **Dehydration**
  During treatment with Wegovy, you may feel sick (nausea) or be sick (vomiting), or have diarrhoea. These side effects can cause dehydration (loss of fluids). It is important that you drink enough fluids to prevent dehydration. This is especially important if you have kidney problems. Talk to your doctor if you have any questions or concerns.

• **Inflammation of the pancreas**
  If you have severe and on-going pain in the stomach area (see section 4) – see a doctor straight away as this could be a sign of inflamed pancreas (acute pancreatitis).

• **People with type 2 diabetes**
  Wegovy cannot be used as a substitute for insulin. Do not use Wegovy in combination with other medicines that contain GLP-1 receptor agonists (such as liraglutide, dulaglutide, exenatide or lixisenatide).

• **Low blood sugar (hypoglycaemia)**
  Taking a sulfonylurea or an insulin with Wegovy might increase the risk of getting low blood sugar levels (hypoglycaemia). Please see section 4 for the warning signs of low blood sugar levels. Your doctor may ask you to test your blood sugar levels. This will help your doctor decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar.

• **Diabetic eye disease (retinopathy)**
  If you have diabetic eye disease and are using insulin, this medicine may lead to a worsening of your vision, and this may require treatment. Fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disease. If you have diabetic eye disease and experience eye problems while taking this medicine, talk to your doctor.

Children and adolescents
This medicine is not recommended in children and adolescents under 18 years as the safety and effectiveness in this age group have not been established.

Other medicines and Wegovy
Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines.
In particular, tell your doctor, pharmacist or nurse if you are using medicines containing the following:

- Warfarin or other similar medicines taken by mouth to reduce blood clotting (oral anticoagulants). When you start treatment with e.g. warfarin or similar medicines, frequent blood testing to determine the ability of your blood to clot may be required.

**Pregnancy and breast-feeding**
This medicine should not be used during pregnancy, as it is not known if it may affect your unborn child. Therefore, it is recommended to use contraception while using this medicine. If you wish to become pregnant, you should stop using this medicine at least two months in advance. If you become or are pregnant, think you may be pregnant or are planning to have a baby when using this medicine, talk to your doctor straight away, as your treatment will need to be stopped.

Do not use this medicine if you are breast-feeding, as it is unknown if it passes into breast milk.

**Driving and using machines**
Wegovy is unlikely to affect your ability to drive and use machines. Some patients may feel dizzy when taking Wegovy mainly during the first 4 months of treatment (see section 4). If you feel dizzy be extra careful while driving or using machines. If you need any further information, talk to your doctor, pharmacist or nurse.

**People with type 2 diabetes**
If you use this medicine in combination with a sulfonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. Avoid driving or using machines if you get any signs of low blood sugar. See section 2, ‘Warnings and precautions’ for information on increased risk of low blood sugar and section 4 for the warning signs of low blood sugar. Talk to your doctor for further information.

**Wegovy contains sodium**
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

### 3. How to use Wegovy

Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.

#### How much to use
The recommended dose is 2.4 mg once weekly.
Your treatment will start at a low dose which will be gradually increased over 16 weeks of treatment.
- When you first start using Wegovy, the starting dose is 0.25 mg once weekly.
- Your doctor will instruct you to gradually increase your dose every 4 weeks until you reach the recommended dose of 2.4 mg once weekly.
- Once you reach the recommended dose of 2.4 mg, do not increase this dose further.
- In case you are feeling very bothered by sickness (nausea) or by being sick (vomiting) talk with your doctor about delaying dose escalation or lowering to the previous dose until symptoms have improved.

Usually, you will be told to follow the table below.

<table>
<thead>
<tr>
<th>Dose escalation</th>
<th>Weekly dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 1–4</td>
<td>0.25 mg</td>
</tr>
<tr>
<td>Week 5–8</td>
<td>0.5 mg</td>
</tr>
<tr>
<td>Week 9–12</td>
<td>1 mg</td>
</tr>
<tr>
<td>Week 13–16</td>
<td>1.7 mg</td>
</tr>
<tr>
<td>From week 17</td>
<td>2.4 mg</td>
</tr>
</tbody>
</table>
Your doctor will assess your treatment on a regular basis.

**How Wegovy is given**

Wegovy is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.

- The best places to give the injection are the front of your upper arm, upper legs or stomach.
- Before you use the pen for the first time, your doctor, pharmacist or nurse will show you how to use it.

Detailed instructions on how to use the pen are on the other side of this leaflet.

**People with type 2 diabetes**

Tell your doctor if you have type 2 diabetes. Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar.

**When to use Wegovy**

- You should use this medicine once a week and if possible, on the same day each week.
- You can give yourself the injection at any time of the day – regardless of meals.

If necessary, you can change the day of your weekly injection of this medicine as long as it has been at least 3 days since your last injection. After selecting a new dosing day, continue with once a week dosing.

**If you use more Wegovy than you should**

Talk to your doctor straight away. You may get side effects such as feeling sick (nausea), being sick (vomiting) or have diarrhoea, which may cause dehydration (loss of fluids).

**If you forget to use Wegovy**

If you forgot to inject a dose and:

- it is 5 days or less since you should have used Wegovy, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.
- it is more than 5 days since you should have used Wegovy, skip the missed dose. Then inject your next dose as usual on your next scheduled day.

Do not use a double dose to make up for a forgotten dose.

**If you stop using Wegovy**

Do not stop using this medicine without talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Serious side effects**

**Common** (may affect up to 1 in 10 people)

- Complications of diabetic eye disease (diabetic retinopathy). If you have diabetes you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine.
Uncommon (may affect up to 1 in 100 people)
• Inflamed pancreas (acute pancreatitis). Signs of inflamed pancreas may include severe and long-lasting pain in your stomach, the pain may move to your back. You should see your doctor immediately if you experience such symptoms.

Rare (may affect up to 1 in 1,000 people)
• Severe allergic reactions (anaphylactic reactions, angioedema). You should seek immediate medical help and inform your doctor straight away if you get symptoms such as breathing difficulty, swelling, light-headedness, fast heartbeat, sweating and loss of consciousness or rapid swelling under the skin in areas such as the face, throat, arms and legs, which can be life threatening if throat swelling blocks the airway.

Other side effects

Very common (may affect more than 1 in 10 people)
• headache
• feeling sick (nausea)
• being sick (vomiting)
• diarrhoea
• constipation
• stomach pain
• feeling weak or tired
– these are mainly seen during dose escalation and usually go away over time.

Common (may affect up to 1 in 10 people)
• feeling dizzy
• upset stomach or indigestion
• burping
• gas (flatulence)
• bloating of the stomach
• inflamed stomach (‘gastritis’) – the signs include stomach-ache, feeling sick (nausea) or being sick (vomiting)
• reflux or heartburn – also called ‘gastro-oesophageal reflux disease’
• gallstones
• hair loss
• injection site reactions
• low blood sugar (hypoglycaemia) in patients with type 2 diabetes.

The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking.

Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs.

Low blood sugar is more likely to happen if you also take a sulphonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine.

Uncommon (may affect up to 1 in 100 people)
• low blood pressure
• feeling dizzy or lightheaded on standing or sitting up because of a drop in blood pressure
• fast heartbeat
• increase of pancreatic enzymes (such as lipase and amylase) shown in blood tests.

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. **How to store Wegovy**

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the pen label and carton after ‘EXP’.
The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C). Do not freeze. Keep away from the cooling element. Always store the pen in the original carton in order to protect from light.
Wegovy may be stored unrefrigerated for up to 28 days at a temperature not above 30°C.
Discard the pen if it has been exposed to light or temperatures above 30°C, has been out of the refrigerator for more than 28 days, or has been frozen.

Do not use this medicine if you notice that the solution is not clear and colourless.

**After use:** The pen is for single use and contains one dose only. Discard pen after use.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Wegovy contains**

– The active substance is semaglutide.

  **Wegovy 0.25 mg solution for injection**
  Each pre-filled pen contains 0.25 mg semaglutide in 0.5 mL.

  **Wegovy 0.5 mg solution for injection**
  Each pre-filled pen contains 0.5 mg semaglutide in 0.5 mL.

  **Wegovy 1 mg solution for injection**
  Each pre-filled pen contains 1 mg semaglutide in 0.5 mL.

  **Wegovy 1.7 mg solution for injection**
  Each pre-filled pen contains 1.7 mg semaglutide in 0.75 mL.

  **Wegovy 2.4 mg solution for injection**
  Each pre-filled pen contains 2.4 mg of semaglutide in 0.75 mL.

– The other ingredients are disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections.

**What Wegovy looks like and contents of the pack**

Wegovy is a clear and colourless solution for injection in a pre-filled disposable pen.

Each pen contains one dose only.

Pack size of 4 pre-filled pens.

**Marketing Authorisation Holder and Manufacturer**

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Package leaflet: Information for the patient

Wegovy

Wegovy 0.25 mg solution for injection in pre-filled pen
Wegovy 0.5 mg solution for injection in pre-filled pen
Wegovy 1 mg solution for injection in pre-filled pen
Wegovy 1.7 mg solution for injection in pre-filled pen
Wegovy 2.4 mg solution for injection in pre-filled pen

semaglutide

Use Wegovy one time each week

Instructions on how to use Wegovy pen

Important information before you start

The package contains one package leaflet and four Wegovy pre-filled pens.

This part of the package leaflet instructs on how to use the pen. For further information regarding your medicine please refer to the other side of this package leaflet.

Each pen is only to be used once.
It comes with:
• one pre-set dose.
• a needle cover that hides the built-in needle before, during and after use.
• an automatic dosing mechanism that starts when the needle cover is pressed against your skin as described by your doctor or nurse.

When injecting the dose, a yellow bar will appear in the pen window. Do not lift the pen before the yellow bar has stopped moving. If you do, the automatic dosing will continue, but you may not receive your full dose.

The needle cover will lock when the pen is removed from your skin. You cannot pause the injection and restart it later.

People who are blind or have vision problems should not use Wegovy pen without help from a person trained to use Wegovy.

Always follow these user instructions and any directions given by your doctor or nurse.
Before use

Expiry date (on the back)
Check that Wegovy has not expired

Always check you have the correct medicine and dose strength. Either:

Pen window
Check that Wegovy is clear and colourless. Air bubbles are normal. They do not affect your dose.

Needle cover
Needle is hidden inside

Pen cap
Remove it just before injecting Wegovy

After use

Pen window
Check that the yellow bar has stopped moving to make sure you received your full dose

Needle cover
Locks after use

EXP/ XX/XXXX
Batch: AB1234

0.25 mg  0.5 mg  1 mg  1.7 mg  2.4 mg
How to use your Wegovy

1. Prepare for your injection.
   Check your Wegovy pen and be careful not to use your pen if:
   1. it has expired
   2. it appears to have been used or damaged, e.g. if it has been dropped or stored incorrectly
   3. the medicine looks cloudy.

Choose your injection site
Choose an injection site in one of the body areas marked below. You can choose your upper arms, upper legs or stomach (keep a 5 cm distance from your belly button).

You may inject in the same body area each week, but make sure it is not in the same spot as used the last time.

Upper arms
Stomach
Upper legs

2. Remove pen cap.
Pull the pen cap straight off your pen.
3. Inject Wegovy.

Press the pen firmly against your skin until the yellow bar has stopped moving.

If the yellow bar does not start moving, press the pen more firmly against your skin.

Click 1
The injection starts.

Click 2
Keep holding for a few seconds until yellow bar stops moving.

Yellow bar has stopped moving. The injection is complete.
Lift the pen slowly and safely dispose of the pen.

How do I handle my pen safely?

For information regarding your medicine please refer to the other side of this package leaflet.

- The pen is for a single injection of Wegovy under the skin once a week and should be used by one person only.

- Always refer to the instructions on the other side of this package leaflet and ensure you have been shown how to use these pens by your doctor or nurse.

- Always keep Wegovy pens out of sight and reach of children. Also, keep the pen cap away from children to prevent them from swallowing it.

- Treat your pen with care and do not expose it to any kind of liquid. Rough handling or misuse may cause your pen to give less than the full dose or no dose at all.
• Keep the pen cap on until you are ready to inject. Your pen will no longer be sterile if you store an unused pen without the cap, if you pull the pen cap off and put it on again, or if the pen cap is missing. This could lead to an infection.

• Be careful when handling your pen before use and do not touch the needle or the needle cover. The hidden needle can cause needle stick injuries.

• Each pen contains one weekly dose and cannot be reused. Dispose of it after use.

How do I store my unused pens?

For information regarding storage see section 5 on the other side of this package leaflet.

How do I dispose of my pens?

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.